AMPHASTAR PHARMACEUTICALS IN
AMPHNASDAQTrading Snapshot
- Day Range
- $754.32 β $773.56
- 52-Week Range
- $16.65 β $29.52
- Volume
- $2.93B
- Avg Volume
- $2.62B
- Shares Outstanding
- 44.1M
- Next Earnings
- Dec 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $720M
- Last Q Revenue
- $184M
- P/E Ratio
- 15.7
- P/S Ratio
- 1.7x
- EPS (TTM)
- $1.80
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β9.4%
Why Investors Own AMPH
- βHigh-growth profile β revenue up +25.4% YoY with expanding US Equity exposure.
- βHealthy economics β 29% gross margin and 7% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
AMPHASTAR PHARMACEUTICALS IN
AMPHAbout AMPHASTAR PHARMACEUTICALS IN
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
AMPHASTAR PHARMACEUTICALS IN tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift AMPH price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
AMPHASTAR PHARMACEUTICALS IN announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.